CNTG - CENTOGENE N.V. Price to Earnings Adjusted for Growth Rate

Centogene N.V. is mitigating cyclicality risks by selling digital biodata to global pharma behemoths. The PEG ratio demonstrates the business's dependence on test accuracy and medical data protection, with the value stabilizing at 0.00. Despite the value of the global genetics bank, financial constraints are hindering the full monetization of the software, limiting the growth potential of the share price.

Centogene (CNTG): PEG Multiple from 07/04/2022 to 08/17/2024

Analytical breakdowns for CENTOGENE (CNTG)

- current price and projected stock value:

Price Chart Centogene N.V.|CNTG - Consensus Target

- market capitalization statistics:

Market Value CENTOGENE, N.V.|CNTG - Total Company Value

- shareholders' equity book value data:

Net Assets per Share CENTOGENE|CNTG - Book Capitalization|Market Capitalization to Book Value centogene.com|CNTG - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

CNTG - Company Net Income|Expected Net Profit Centogene N.V.|CNTG - P/E Multiple|Forward Price to Earnings Multiple Centogene|CNTG - PEG Multiple|Company Value to EBITDA CENTOGENE, N.V.|CNTG - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months CENTOGENE|CNTG - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months centogene.com|CNTG - Net earnings per share growth this year|Expected earnings per share trend next year Centogene N.V.

General company analysis:CNTG - CENTOGENE, N.V.

Centogene N.V. (CNTG) status as an authoritative leader in precision genetics ensures high B2B loyalty among pharma behemoths, making the analysis of price dynamics particularly significant. The current PEG ratio at 0.00 compares the market multiple with expected business expansion; a value below one signals that the asset is undervalued relative to its potential, confirming the company's fundamental stability.

Competitors of Centogene N.V.